4-benzyl-1-butyrylpiperazine | 314728-81-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-benzyl-1-butyrylpiperazine
• 英文别名: 1-(4-Benzylpiperazin-1-yl)butan-1-one
• CAS: 314728-81-9
• 化学式: C₁₅H₂₂N₂O
• mdl: MFCD01355363
• 分子量: 246.352
• InChiKey: DQXACBJQQWXRHG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-benzyl-1-butyrylpiperazine 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 生成 1-(1-哌嗪基)-1-丁酮
  参考文献：
  名称：

  New antiproliferative benzoindolinothiazepines derivatives

  摘要：

  New benzoindolinothiazepines containing a piperazine moiety are described as potent antiproliferative agents against PC3 human prostatic cell lines. This activity could be explained by an accumulation of cells in G1 phase. (C) 2004 Elsevier SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2004.10.008
• 作为产物：
  描述：

  1-苄基哌嗪 、 丁酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 4-benzyl-1-butyrylpiperazine
  参考文献：
  名称：

  New antiproliferative benzoindolinothiazepines derivatives

  摘要：

  New benzoindolinothiazepines containing a piperazine moiety are described as potent antiproliferative agents against PC3 human prostatic cell lines. This activity could be explained by an accumulation of cells in G1 phase. (C) 2004 Elsevier SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2004.10.008
• 作为试剂：
  描述：

  1-苄基哌嗪 、 丁酰氯 、 三乙胺 在 ice 、 potassium hydrogensulfate 、 碳酸氢钠 、 Brine 、 Sodium sulfate-III 、 二氯甲烷 、 crude material 、 toluene-ethyl acetate 、 4-benzyl-1-butyrylpiperazine 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 以to give 432 mg of colorless oil的产率得到4-benzyl-1-butyrylpiperazine
  参考文献：
  名称：

  Composition for treatment of tuberculosis

  摘要：

  本发明涉及一种药物组合物，包括式（1）中的化合物，其中R1是可选取代的苯基、可选取代的吡啶基或可选取代的吲哚基；R2是（CH2）n，其中n为0、1、2、3或4；R3是（CH2）mR3A，其中m为0、1、2、3或4，R3A是甲基、异丙基、叔丁基、OCH3、OH、可选取代的苯氧基、C≡CH、C≡N、可选取代的苯基、呋喃基或噻吩基；A是含有X1的环，X1的含义为O、S、NH、N（CH3）或CH2；X2是O、S或NH；以及式（2）中的化合物，其中R4是可选取代的苯基、可选取代的吡啶基、可选取代的吲哚基、—NR7R8；或—NH—N═CH—R9；且取代基R5到R9的含义在说明书中有所说明，特别是乙硫异烟胺。该药物组合物可用于治疗多药耐药性结核病等疾病。

  公开号：

  US08912329B2

文献信息

• DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS
  申请人：Matsuyama Hironori

  公开号：US20100004438A1

  公开（公告）日：2010-01-07

  An object of the present invention is to provide a medicinal drug much improved in anti tumor activity and excellent in safety. According to the present invention, there is provided a medicinal drug containing a compound represented by the following general formula (1) or a salt thereof as an active ingredient: [Formula 1] wherein X 1 represents a nitrogen atom or a group —CH═, R 1 represents a group -Z-R 6 , in which Z represents a group —CO—, a group —CH(OH)— or the like, R 6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R 2 represents a hydrogen atom or a halogen atom, Y represents a group —O—, a group —CO—, a group —CH(OH)— or a lower alkylene group, and A represents [Formula 2] wherein R 3 represents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, R 4 represents an imidazolyl lower alkyl group or the like.

  本发明的一个目的是提供一种在抗肿瘤活性方面大大改进且安全性优异的药物。根据本发明，提供了一种包含以下一般式（1）所表示的化合物或其盐作为活性成分的药物：[式1]其中X1代表氮原子或基团—CH═，R1代表一个基团-Z-R6，其中Z代表基团—CO—，基团—CH(OH)—或类似的基团，R6代表一个含有1至4个氮原子、氧原子或硫原子的5至15个成员的单环、双环或三环饱和或不饱和杂环基团，R2代表氢原子或卤原子，Y代表基团—O—，基团—CO—，基团—CH(OH)—或低碳烷基基团，A代表[式2]其中R3代表氢原子、低碳氧基基团或类似基团，p代表1或2，R4代表咪唑基低碳基团或类似基团。
• Aromatic Compounds
  申请人：Fukushima Tae

  公开号：US20070270422A1

  公开（公告）日：2007-11-22

  The present invention provides a novel compound, which has an excellent effect of suppressing the generation of collagen and less side effects, with being excellent in terms of safety. The compound of the present invention is represented by the following general formula (1): [wherein X 1 represents a nitrogen atom or a group —CH═; R 1 represents a group -Z-R 6 , wherein Z represents a group —CO—, a group —CH(OH)—, or the like, and R 6 represents a 5- to 15-membered monocyclic, dicyclic, or tricyclic, saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms, or sulfur atoms; R 2 represents a hydrogen atom, a halogen atom or a lower alkylene group; Y represents a group —O—, a group —CO—, a group —CH(OH)—, a lower alkylene group, or the like; and A represents a group or the like, wherein R 3 represents a hydrogen atom, a lower alkoxy group, or the like, p represents 1 or 2, and R 4 represents an imidazolyl lower alkyl group or the like.

  本发明提供了一种新型化合物，具有抑制胶原生成的优异效果，并且具有较少的副作用，在安全性方面表现出色。本发明的化合物由以下通式（1）表示：[其中X1代表氮原子或基团—CH═；R1代表基团-Z-R6，其中Z代表基团—CO—、基团—CH(OH)—或类似基团，而R6代表具有1到4个氮原子、氧原子或硫原子的5-到15元的单环、双环或三环、饱和或不饱和杂环基团；R2代表氢原子、卤素原子或低碳链基团；Y代表基团—O—、基团—CO—、基团—CH(OH)—、低碳链基团或类似基团；A代表基团或类似基团，其中R3代表氢原子、低碳醚基团或类似基团，p代表1或2，而R4代表咪唑基低碳基团或类似基团。
• COMPOSITION FOR TREATMENT OF TUBERCULOSIS
  申请人：Schoenmakers Ronald

  公开号：US20120101080A1

  公开（公告）日：2012-04-26

  The invention relates to a pharmaceutical composition comprising a compound of formula (1) wherein R 1 is optionally substituted phenyl, optionally substituted pyridyl or optionally substituted indolyl; R 2 is (CH 2 ) n wherein n is 0, 1, 2, 3 or 4; R 3 is (CH 2 ) m R 3A wherein m is 0, 1, 2, 3 or 4, and R 3A is methyl, isopropyl, tert-butyl, OCH 3 , OH, optionally substituted phenoxy, C≡CH, C≡N, optionally substituted phenyl, furanyl or thienyl; A is a ring containing X 1 with the meaning O, S, NH, N(CH 3 ) or CH 2 ; and X 2 is O, S or NH; and a compound of formula (2) wherein R 4 is optionally substituted phenyl, optionally substituted pyridyl, optionally substituted indolyl, —NR 7 R 8 ; or —NH—N═CH—R 9 ; and substituents R 5 to R 9 have the meanings indicated in the description, in particular ethionamide. The pharmaceutical composition is useful, e.g., in the treatment of multidrug-resistant tuberculosis.

  本发明涉及一种药物组合物，其中包含式（1）的化合物，其中R1是可选取代苯基，可选取代吡啶基或可选取代吲哚基；R2是（CH2）n，其中n为0、1、2、3或4；R3是（CH2）mR3A，其中m为0、1、2、3或4，R3A是甲基、异丙基、叔丁基、OCH3、OH、可选取代苯氧基、C≡CH、C≡N、可选取代苯基、呋喃基或噻吩基；A是一个含有X1环，X1的含义是O、S、NH、N(CH3)或CH2；X2是O、S或NH；以及式（2）的化合物，其中R4是可选取代苯基，可选取代吡啶基，可选取代吲哚基，—NR7R8；或—NH—N═CH—R9；和取代基R5至R9在说明书中有所示，特别是乙硫异烟胺。该药物组合物在治疗多药耐药结核病方面具有用途。
• AROMATIC COMPOUND
  申请人：FUKUSHIMA Tae

  公开号：US20120238750A1

  公开（公告）日：2012-09-20

  The compound of the present invention is represented by the following general formula (1): [wherein X 1 represents a nitrogen atom or a group —CH═; R 1 represents a group —Z—R 6 , wherein Z represents a group —CO—, a group —CH(OH)—, or the like, and R 6 represents a 5- to 15-membered monocyclic, dicyclic, or tricyclic, saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms, or sulfur atoms; R 2 represents a hydrogen atom, a halogen atom or a lower alkylene group; Y represents a group —O—, a group —CO—, a group —CH(OH)—, a lower alkylene group, or the like; and A represents a group or the like, wherein R 3 represents a hydrogen atom, a lower alkoxy group, or the like, p represents 1 or 2, and R 4 represents an imidazolyl lower alkyl group or the like.

  本发明的化合物由以下通式（1）表示：[其中X1表示氮原子或基团—CH═; R1表示基团—Z—R6，其中Z表示基团—CO—、基团—CH（OH）—或类似物，而R6表示具有1至4个氮原子、氧原子或硫原子的5至15环的单环、双环或三环、饱和或不饱和的杂环基团; R2表示氢原子、卤素原子或较低的烷基链; Y表示基团—O—、基团—CO—、基团—CH（OH）—、较低的烷基链或类似物; A表示基团或类似物，其中R3表示氢原子、较低的烷氧基或类似物，p表示1或2，而R4表示咪唑基较低的烷基链或类似物。
• Molecular Simplification of 1,4-Diazabicyclo[4.3.0]nonan-9-ones Gives Piperazine Derivatives That Maintain High Nootropic Activity
  作者：Dina Manetti、Carla Ghelardini、Alessandro Bartolini、Silvia Dei、Nicoletta Galeotti、Fulvio Gualtieri、Maria Novella Romanelli、Elisabetta Teodori

  DOI：10.1021/jm000972h

  日期：2000.11.1

  Several 4-substituted 1-acylpiperazines, obtained by molecular simplification of 4-substituted 1,4-diazabicyclo[4.3.0]nonan-9-ones, have been synthesized and tested in vivo on the mouse passive avoidance test, to evaluate their nootropic activity. The results show that, apparently, an N-acylpiperazine group can mimic the 2-pyrrolidinone ring of 1,4-diazabicyclo[4.3.0]nonan-9-one, as the compounds of the new series maintain high nootropic activity. Moreover molecular simplification produces more clear-cut structure-activity relationships with respect to the parent series. The mechanism of action also appears to be similar in the two series. In fact, although the molecular mechanism remains to be elucidated, the most potent compound of each class (DM232 and 13, DM235) is able to increase acetylcholine release in rat brain. Piperazine derivatives represent a new class of nootropic drugs with an in vivo pharmacological profile very similar to that of piracetam, showing much higher potency with respect to the reference compound. Among the compounds studied, 13 (DM235) shows outstanding potency, being active at a dose of 0.001 mg kg(-1) sc.